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ABSTRACT
Objectives: To evaluate the reliability, responsiveness, and
validity of a four-graded symptom severity scale (none,
mild, moderate, severe) and an eight-graded frequency scale
(number of days with symptoms during past week) for assess-
ment of heartburn severity and frequency in patients with
symptoms of heartburn but without esophagitis.
Methods: Data were taken from two 4-week clinical trials
comparing esomeprazole 20 mg and/or 40 mg to omeprazole
20 mg. Both scales were analyzed in terms of mean scores
and treatment success rates, after dichotomization to “treat-
ment success” variables.
Results: Heartburn severity reliability was higher when
assessed by patient diary cards than by the investigator (intra-
class correlation coefﬁcients were 0.79 and 0.59, respectively;
corresponding ﬁgures for heartburn frequency were 0.77 and
0.78). There was good agreement between investigator and
diary card assessments for the dichotomized variables “com-
plete resolution” and “adequate relief” from heartburn. High
correlation between investigator- and diary card-assessed
heartburn severity and frequency was apparent. Responsive-
ness was high, as shown by comparing 4-week treatment
success rates to the patients’ perception of treatment effect
according to the Overall Treatment Effect questionnaire.
Construct validity was good (kappa values approximately
0.70 for agreement between complete resolution and the
dichotomized Gastrointestinal Symptom Rating Scale [GSRS]
Heartburn item). Correlations between heartburn severity
and frequency and the GSRS Heartburn item were similarly
high.
Conclusion: The four-graded heartburn severity and eight-
graded frequency scales are reliable, responsive, and valid
when used in clinical trials of patients with symptoms of
gastroesophageal reﬂux disease, irrespective of the type of
assessment (investigator assessment or patient diary cards).
Keywords: four-graded scale, gastroesophageal reﬂux
disease, heartburn, validation.
Introduction
Resolution of troublesome symptoms is one of the
primary treatment goals in the management of patients
with endoscopy-negative gastroesophageal reﬂux
disease (GERD) [1]. The major symptoms of GERD
assessed in clinical trials are heartburn and acid regur-
gitation [2]. Of these, heartburn is by far the most
common and is generally regarded as being the hall-
mark symptom of GERD. For patients with
endoscopy-negative GERD, heartburn is considered to
be the most relevant outcome measure [1]. In order to
assess heartburn severity in clinical trials, a four-
graded scale has often been used [3–5] both by inves-
tigators and by patients using daily diary cards.
Treatment comparisons are sometimes based on a dif-
ference in mean severity score, but more often they are
based on a difference in treatment success rate, where
the deﬁnition of treatment success is a dichotomization
of the four-graded scale. For example, treatment
success may be deﬁned as complete resolution of heart-
burn (no heartburn during the last 7 days) before a
certain clinical visit or time point, or as adequate relief
of heartburn (at most 1 day of mild heartburn during
the last 7 days), and may be based on either the inves-
tigator’s assessment [4] or patient diary cards [5]. A
difference in treatment success rate is easier to under-
stand than a difference in mean scores, but may be less
efﬁcient in terms of statistical power.
The aim of this article is to validate outcome vari-
ables derived from the four-graded severity scale and
from an eight-graded frequency scale, in terms of reli-
ability, responsiveness, and validity. For the assessment
of both heartburn severity and frequency, a 7-day ref-
erence period was used.
Methods
Data presented here relate to two clinical studies [6] in
patients with heartburn but without endoscopic ﬁnd-
ings of erosive esophagitis according to the Los
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Angeles classiﬁcation (grades A–D). These double-
blind, randomized, 4-week studies were of almost
identical design; they differed only in terms of location
and treatments. One study (study A), performed in
the United Kingdom, Ireland, and Canada, included
esomeprazole 40 mg, esomeprazole 20 mg, and ome-
prazole 20 mg, and the other, performed in Scandina-
via (study B), included esomeprazole 20 mg and
omeprazole 20 mg. Baseline demographics for the two
studies are presented in Table 1. All patients had a
history of heartburn as their main GERD symptom for
at least 6 months, and had experienced heartburn for
at least 4 days during the week before the baseline
visit. They had all identiﬁed their main symptom as
heartburn, deﬁned as a burning feeling rising from the
stomach or lower part of the chest up toward the neck.
Exclusion criteria included a signiﬁcant condition
likely to affect the outcome of the study and use of a
H2-receptor antagonist or proton pump inhibitor in
the 14 or 28 days, respectively, before the baseline
endoscopy.
Assessments
Gastrointestinal Symptom Rating Scale (GSRS). At
baseline and after 2 and 4 weeks of treatment, patients
answered the validated GSRS questionnaire [7], with
questions relating to the previous 7 days. The GSRS
uses a seven-graded Likert scale to assess symptom
severity: No discomfort at all, Minor, Mild, Moderate,
Moderately severe, Severe, or Very severe discomfort.
It consists of 15 items, one of which is related to
heartburn and worded “Have you been bothered by
HEARTBURN during the past week? (By heartburn
we mean an unpleasant stinging or burning sensation
in the chest.)” All items are phrased in the same way,
grading the discomfort patients’ experience as a result
of various gastrointestinal symptoms such as nausea,
bloating, and diarrhea. The items are mapped into
ﬁve dimensions: Diarrhea, Indigestion, Constipation,
Abdominal pain, and Reﬂux, where the Reﬂux dimen-
sion consists of the Heartburn item and a Regurgita-
tion item. The GSRS is used for the evaluation of
validity of the examined heartburn scales.
Overall Treatment Effect (OTE). After 2 and 4 weeks
of treatment, patients answered the OTE question-
naire. They were asked whether their reﬂux symptoms
(heartburn and/or regurgitation) had improved, wors-
ened, or remained unchanged. Patients then rated the
degree of the improvement or worsening since start
of treatment. For patients whose symptoms had
improved, the categories of response were as follows:
OTE scale For analysis
A very great deal better A very great deal better
A great deal better A great deal better
A good deal better
Moderately better
A good deal better
Somewhat better
A little better Somewhat better
Almost the same, hardly better at all
Unchanged Unchanged
The corresponding categories were used for patients
with worsened symptoms. For the purpose of analyz-
ing responsiveness, some “better” categories were
combined (as shown above) and all “worse” categories
were combined into one (due to the small number of
cases). Although the OTE refers to both heartburn and
regurgitation, heartburn is the dominant symptom. At
baseline, 2 weeks, and 4 weeks, 63%, 41%, and 28%,
respectively, had more severe heartburn than regurgi-
tation, and 32%, 51%, and 64%, respectively, had the
same severity of heartburn and regurgitation. Thus, we
assumed that the OTE primarily measures the per-
ceived change in heartburn.
Both the GSRS and the OTE questionnaires were
completed during the visits to the clinic before any
other assessments were performed.
The four-graded scale. The investigator assessments of
patients’ overall heartburn severity and heartburn fre-
quency (number of days with heartburn) were made at
each clinical visit (at baseline and after 2 and 4 weeks
of treatment) with reference to the 7 days before the
visit. Patients themselves assessed and recorded their
heartburn severity on a diary card. Each day, patients
recorded the severity of the most severe heartburn
episode during the night (to be recorded in the
morning) and in the daytime (to be recorded before
bedtime), throughout the 4-week treatment period.
In order to have diary recordings comparable to
investigator assessments, only recordings of daytime
heartburn were used in the present analysis. Both
assessments used the four-graded severity scale:
Table 1 Baseline demographic and clinical characteristics of
the study populations
Characteristic
Study A
patients
Study B
patients
All patients
included
Excluded
patients
N 871 539 1410 542
Males, n (%) 378 (43) 281 (52) 659 (47) 237 (44)
Mean age (SD), year 49 (13) 49 (14) 49 (14) 47 (15)
History of heartburn
episodes, n (%)
<6 months 1 (0) 0 1 (0) 1 (0)
6–12 months 113 (13) 55 (10) 168 (12) 69 (13)
1–5 years 336 (39) 151 (28) 487 (35) 216 (40)
>5 years 421 (48) 333 (62) 754 (53) 256 (47)
Overall heartburn
severity in previous
7 days, n (%)
None 1 (0) 0 1 (0) 0
Mild 197 (23) 100 (19) 297 (21) 120 (22)
Moderate 526 (60) 347 (64) 873 (62) 321 (59)
Severe 147 (17) 92 (17) 239 (17) 101 (19)
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None = 0 no symptoms
Mild = 1 awareness of symptom, but easily
tolerated
Moderate = 2 discomfort sufﬁcient to cause
interference with normal
activities
Severe = 3 incapacitating, with inability to
perform normal activities.
Two treatment success variables were deﬁned using
dichotomization of the severity and frequency assess-
ments: “complete resolution” (no heartburn during the
previous 7 days) and “adequate relief” (at most 1 day
with heartburn rated “mild” during the previous
7 days). These deﬁnitions were applied to both inves-
tigator and patient diary card assessments. In total,
eight variables were examined: the binary treatment
success variables “complete resolution” and “adequate
relief,” and the ordinal variables “heartburn severity”
and “heartburn frequency,” based on investigator
assessment and diary cards completed by the patient.
The ordinal variable heartburn severity has four grades
(with scores given above) when assessed by the inves-
tigator and is the mean score over the last 7 days when
based on diary cards.
Statistical Analysis
Responsiveness. For investigator-assessed heartburn
severity and frequency, standardized response means
were calculated as the difference between the baseline
and 4-week values divided by the standard deviation of
the change. Effect sizes were calculated as the differ-
ence between baseline and 4-week values divided by
the standard deviation at baseline [8]. Effect sizes and
standardized response means were also calculated
for each OTE category. There were no patient diary
assessments before treatment and thus standardized
response means and effect sizes could not be calculated
for the corresponding diary-based ordinal variables.
For diary-based ordinal variables and treatment
success variables, responsiveness was evaluated at
4 weeks using the OTE questionnaire categories as an
anchor. In this evaluation, treatment success rates for
the variables diary-based mean heartburn severity and
mean heartburn frequency were calculated for each
OTE category and the results presented graphically.
If the outcome measure is responsive to change,
effect sizes for patients who were “better” according to
the OTE should be larger than for patients who were
“worse” or “unchanged.” Consequently, patients “a
very great deal better” should have the largest effect
size. Similarly, mean heartburn severity and frequency
at 4 weeks should be highest for patients who were
“worse” or “unchanged” and lowest for those being
“a very great deal better.” In the same way, for
dichotomized variables, the treatment success rate
should be higher for those who are “better” than for
those who are “unchanged” or “worse.”
Reliability. The ability of the heartburn variables to
yield reproducible results was assessed using the test–
retest approach, where patients in a stable condition
repeatedly assess their symptoms. In this analysis of
reliability, we used assessments made at 2 and 4 weeks
in patients who had the same answer to the OTE
questionnaire at these time points. Reliability for the
ordinal variables was evaluated by estimating intrac-
lass correlation coefﬁcients (ICCs). For the dichoto-
mized outcome variables “complete resolution” and
“adequate relief,” reliability was evaluated in terms of
kappa values. The ICCs were calculated from an
anova with visit and subject as factors [9]. The corre-
lation between investigators’ assessment of heartburn
and the assessment made by patient diary cards may
also serve as a measure of reliability. These two assess-
ments measure the same symptom during the same
time period and thus ﬂuctuation in the patient’s health
status has no impact.
Validity. Construct validity is an assessment of the
degree to which an instrument or scale measures what
it is designed to measure [8]. In this case, the heartburn
assessments under investigation were correlated with
some other assessments of heartburn. Thus, when
using GSRS as the comparator, the Heartburn item of
the GSRS questionnaire was preferred to the reﬂux
dimension scale. Construct validity of the ordinal vari-
ables was assessed by correlating the heartburn sever-
ity and frequency variables with the Heartburn item on
the GSRS questionnaire, using Pearson correlation
analysis. The validity of the dichotomized treatment
success variable “complete resolution” of heartburn
was assessed in terms of kappa values. For the latter
evaluation the GSRS Heartburn item was dichoto-
mized with treatment success deﬁned as “No discom-
fort at all.” As the GSRS item does not separate
severity from frequency, the dichotomized variable
“adequate relief” has no direct dichotomized GSRS
comparator. Instead, the validity of “adequate relief”
was examined by correlating it with the original (not
dichotomized) GSRS Heartburn item. In this examina-
tion, Pearson correlation coefﬁcients were used as a
substitute for kappa values.
Results
Of the 1952 patients in the intention-to-treat popula-
tion, complete data for the OTE questionnaire and
investigator- and diary card-assessed heartburn were
available for 1410 patients. Baseline characteristics did
not reveal any relevant differences between the two
studies included in the analysis (Table 1). Most exclu-
sion from the analysis was due to incomplete diary
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card recordings, and the key demographic variables for
the excluded patients were essentially the same as for
those included in this analysis (Table 1).
Responsiveness
Both “complete resolution” and “adequate relief”
were responsive, as shown by the comparison of
4-week treatment success rates with the patients’ per-
ception of treatment effect using the OTE que-
stionnaire (Fig. 1). The responsiveness of diary
card-assessed heartburn severity and frequency is illus-
trated graphically in Figure 2. Table 2 presents effect
sizes and standardized response means by OTE classi-
ﬁcation for the investigator-assessed heartburn severity
and frequency scales.
Reliability. Out of the 1410 evaluable patients, 707
had the same answer to the OTE questionnaire at
weeks 2 and 4 and were included in the evaluation of
test–retest reliability. The reliability of heartburn sever-
ity was higher when assessed by patient diary cards
than when assessed by the investigator (ICC values of
0.79 and 0.59, respectively). The corresponding ﬁgures
for heartburn frequency were 0.77 and 0.78. For
investigator- and diary card-assessed heartburn, kappa
values for the dichotomized variable “complete reso-
lution” were 0.52 and 0.57, respectively, and for
“adequate relief” kappa values were 0.59 for both.
Measuring agreement between investigator- and
diary card-assessments, kappa values were 0.76 with
regard to both “complete resolution” and “adequate
relief” from heartburn. Investigator assessment gave a
slightly higher overall proportion with “complete reso-
lution” and “adequate relief” than patient-recorded
diaries (Table 3). The correlation between the
investigator- and diary card-assessed heartburn sever-
ity was 0.71; for heartburn frequency the correlation
was 0.85.
Validity. The dichotomized variable “complete resolu-
tion” showed good agreement with the dichotomized
GSRS Heartburn item after 4-week treatment (kappa
values for investigator- and diary card-assessed heart-
burn were 0.70 and 0.69, respectively). Correlations
between the ordinal heartburn severity variable and
the GSRS Heartburn item were 0.72 for investigator-
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assessed heartburn and 0.71 for diary card-assessed
heartburn at 4 weeks. The correlation between heart-
burn frequency and the GSRS Heartburn item was
similar: 0.68 for investigator-assessed heartburn and
0.67 for diary card-assessed heartburn. The correla-
tion between diary-based “adequate relief” and the
GSRS Heartburn item was 0.62; the corresponding
value for investigator-based “adequate relief” was
0.64.
Discussion
The development of the GSRS started in 1988, when a
rating scale comprising 15 interview-based questions
was proposed for a comprehensive evaluation of treat-
ment effects [10]. This rating scale was later modiﬁed to
become a self-administered questionnaire with three
dimensions. The current subgrouping of the items into
ﬁve dimensions [11] has been validated with regard to
validity, reliability, and responsiveness [7]. Neverthe-
less, the GSRS does not distinguish between severity
and frequency and thus the examined variables can give
additional information about the symptomatology.
The relationship between heartburn severity/
frequency and the perception that the medication gives
sufﬁcient control of heartburn was studied in a trial
of omeprazole in patients with endoscopy-negative
GERD [12]. After 4 weeks of treatment, 99% of those
with complete resolution and 92% of those with 1 day
of mild heartburn stated that the trial medication gave
sufﬁcient control of their heartburn, compared to only
10% of those with mild heartburn 5 to 7 days in the
past week. Only 1% of those with moderate or severe
heartburn after 4 weeks of treatment had sufﬁcient
control of heartburn. Thus, both frequency and sever-
ity of heartburn are valuable for interpreting the
outcome in clinical terms, and were included in the
present analysis.
In studies where treatments are compared in terms of
mean severity score, the scale should preferably have
more than four categories [13]. Nevertheless, the results
from the present study indicate that even a four-graded
severity scale could be used satisfactorily in such an
analysis of acid-suppressive therapies for GERD.
For scales with seven grades, a change in mean score
of 0.5 grades is often regarded as being clinically rel-
evant [14]. In some studies evaluating a clinically rel-
evant change the OTE has been used as an anchor [14],
and the change is deﬁned as the difference inmean score
between patients who are “unchanged” and patients
being “somewhat better” [15]. If this deﬁnition is
applied to the diary-assessed heartburn severity vari-
able, then a clinically relevant change would be 0.35
(1.02 minus 0.67; see Fig. 2). Similarly, using data from
Table 2, one can calculate that the clinically relevant
change for the investigator-assessed four-graded scale
for heartburn severity is 0.29 (0.96minus 0.67). Table 2
shows that 13% (183/1410) of the patients were
“unchanged” or “worse” after 4 weeks of treatment.
One reason for this lack of effect may be that the cause
of heartburn was not acid-related.
The test–retest reliabilities for the binary treatment
success variables lie in the range of 0.5 to 0.6, which
may seem somewhat low but can be regarded as being
of “fair” to “good” according to Fleiss [9]. Reliability
was better when assessed as the agreement between
diary- and investigator-based treatment success vari-
ables, with kappa values of 0.76. However, it is pos-
sible that, when answering the investigator’s question,
patients recalled what they had written in the diary
during the preceding week.
Table 2 Change, SRM, and effect size for investigator-assessed heartburn severity during the previous 7 days from baseline to after
4 weeks of treatment, according to the OTE classiﬁcation
OTE classiﬁcation n
Investigator-assessed overall severity change Investigator-assessed frequency change
Change SRM Effect size Change SRM Effect size
Worse 29 0.17 0.19 0.25 0.83 0.38 0.70
Unchanged 154 0.67 0.76 0.96 1.31 0.51 1.06
Somewhat better 67 0.96 1.19 1.36 2.55 0.98 1.88
A good deal better 203 1.19 1.42 1.90 3.75 1.47 2.94
A great deal better 276 1.44 1.75 2.41 4.62 2.07 3.77
A very great deal better 681 1.87 2.68 3.19 5.84 3.93 4.83
All 1410 1.48 1.65 2.40 4.55 1.77 3.69
OTE, Overall Treatment Effect; SRM, standardized response mean.
Table 3 Cross-tabulation of diary- and investigator-assessed
complete resolution and adequate relief
Investigator-assessed
No Yes All
n % n % N %
Complete resolution
Diary-assessed
No 494 35.0 120 8.5 614 43.5
Yes 45 3.2 751 53.3 796 56.5
All 539 38.2 871 61.8 1410 100.0
Adequate relief
Diary-assessed
No 406 28.8 98 7.0 504 35.7
Yes 55 3.9 851 60.4 906 64.3
All 461 32.7 949 67.3 1410 100.0
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Patient diary-recorded heartburn correlated well
with investigator-assessed heartburn at 4 weeks. The
investigator assessment gave a slightly higher pro-
portion of patients with “complete resolution” and
“adequate relief” than the patient diary recordings.
These ﬁndings are in agreement with previous studies
[16,17].
When using ordinal variables, frequency of heart-
burn seems to be an alternative to severity of heart-
burn. Frequency of heartburn shows good agreement
between patient diary recordings and investigator
assessment. The reliability is high and the responsive-
ness, measured as the difference in effect size between
“unchanged” patients and patients “a very great deal
better,” is higher for heartburn frequency than for
heartburn severity. An explanation might be that the
number of days with heartburn during a 7-day period
is a more objective and precise measure than the
overall assessment of heartburn severity during the
same period. Thus, we would recommend choosing
mean heartburn frequency rather than mean heartburn
severity as an outcome measure in clinical trials.
Overall, our results indicate that all the examined
variables are appropriate for use as outcome measures
in clinical trials of endoscopy-negative patients with
symptoms of heartburn. The results are only valid in
such a context and with patients having a distribution
of baseline characteristics similar to those in the clini-
cal trials examined in this study. One limitation there-
fore is that generalization of the results to other patient
populations may not be appropriate. Furthermore, the
symptom studied was heartburn with a speciﬁc scale,
and the results may not be applicable to other GERD
symptoms such as acid regurgitation or dysphagia, or
to other four-graded scales with different categories
and scales with a different number of grades.
Conclusion
To summarize, the heartburn frequency and the four-
graded scale for assessing heartburn severity are reli-
able, responsive, and have good construct validity in
patients with GERD. This applies to both assessments
made by the investigator and assessments made by the
patient using daily diary cards, and also when the scale
is dichotomized into a success variable.
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